Transcriptomic and proteomic analysis stratifies patients with axial spondyloarthritis based on disease activity, structural damage and radiographic progression

Key Points

• Disease severity is linked to specific proteomic biomarkers that may inform treatment strategies for axSpA.
• The analysis found significant molecular pathways associated with radiographic progression and structural damage in axSpA patients.
• Assessment of transcriptomic predictors indicates a correlational framework for understanding disease activity in axial spondyloarthritis.
• These insights may enable the development of targeted therapies based on individual molecular profiles in future clinical settings.